1

NASDAQ: NEO

Company Overview Presentation May 2013

Time Matters. Results Count!

“Improving Patient Care through exceptional cancer genetic testing services!”

2 2

Forward-looking Statements This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements. Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.

3 3

Investment Highlights

• Fast growing pure-play, cancer genetics lab

• Servicing: Oncologists, Pathologists and Hospitals

• “Tech-Only” model creates strategic client partnerships

• Rapidly growing industry undergoing consolidation

• Strong Management Team with large cap lab experience

• Industry leading revenue & test volume growth driven by new test innovation and increasing sales force productivity

• Increasing productivity and operating leverage leading to accelerating cash flow and net income

4 4

Consistent Historical Growth

$0

$10,000

$20,000

$30,000

$40,000

$50,000

$60,00020

04

2005

2006

2007

2008

2009

2010

2011

2012

Annual Revenue ($, 000’s)

0

20,000

40,000

60,000

80,000

100,000

120,000

2004

2005

2006

2007

2008

2009

2010

2011

2012

Tests Performed (000’s)

5 5

Accelerating Cash Flow & Earnings ($, 000's) 2010 2011 2012Total Revenue 34,371$ 43,484$ 59,867$ % Growth 16.6% 26.5% 37.7%

Total Gross Margin 15,783 19,428 26,836 Gross Margin % 45.9% 44.7% 44.8%

Sales & Marketing Exp as a % of Rev 21.8% 16.0% 12.5%Gen & Admin Exp as a % of Rev 31.2% 28.4% 26.5%R&D Exp as a % of Rev 1.5% 1.2% 3.8% SG&A Expenses 18,746 19,837 25,624 Total SG&A as a % of Rev 54.5% 45.6% 42.8%

Adjusted EBITDA (566)$ 2,134$ 5,997$ % Growth NA 181.0%

Net Income/(Loss) (3,303)$ (1,177)$ 65$ Diluted EPS ($0.09) ($0.03) $0.00

Summary Operating MetricsAvg. Revenue/Test 600$ 570$ 522$ % Change -7.1% -4.9% -8.4%

6 6

• Molecular diagnostics transforming lab services industry and fueling rapid growth

– Molecular diagnostics enable physicians to better diagnose diseases and predict therapeutic efficacy

• Clinical Benefits: Effective treatment at an early stage increases patient survival rates

• Healthcare Savings: a) forego spending on ineffective therapies and b) effective intervention at an early stage generally lowers overall treatment cost

– Need for companion diagnostics being driven by rising drug costs and an increase in targeted therapeutics

• Xalkori® - Cost of ~$90,000 annually to treat non-small cell lung cancer. 50 – 61% effective for the ~3% of the population with certain genetic characteristics

• Diagnostic testing can significantly lower healthcare costs and improve clinical outcomes

– Diagnostics represents only 2-3% of total healthcare spend but influence approximately 70% - 80% of physician decisions

• Cancer prevalence expected to increase as U.S. population ages

– 77% of all cancers diagnosed are in people age 55 or older, the fastest growing segment of the US

16% 17% 16%18%

22%25% 25% 26%

11% 13% 12% 13%16%

19% 20% 20%

0%

5%

10%

15%

20%

25%

30%

1980 1990 2000 2010 2020 2030 2040 2050

Perc

ent O

f Pop

ulat

ion

Age 60 and older Age 65 and older

Current

U.S. Population Demographics

Boomer Impact on Cancer Market

Industry Dynamics

7 7

U.S. Cancer Testing Market: $10-12 Billion Hematopoietic

Cancers Solid Tumor Cancers

Total Testing Market: $3 - 4 Billion $7 - 8 Billion

Est. Genetic Mkt. (TAM) ~$1 - 2 Billion

~$1 - 2 Billion

Patients in Treatment: 850,000 7.0 million

New Diagnoses/Yr.: 150,000 1.45 million

Specimen Types: Bone Marrow (350K/Yr) Per. Blood (150K/Yr)

Lymph Nodes

Tiss. Biopsies (8-10MM) Fine Needle Aspirates

Other Bodily Fluids TAM % Neo Addresses: 90-100% 30-40%

Neo Revenue Split: ~80% ~20%

8 8

Cancer Testing Market Characteristics

• Highest growth segment of lab Industry - ~20% annual growth in genetics testing - 8-10% annual growth in related AP testing

• Approx. 360 Genetic Labs in the U.S. - 2/3 affiliated with academic institutions - Approximately 20% perform 80% of testing - Only 15-20 labs with national reach

• High pace of consolidation - Recent examples include: Target Acquiror TV/LTM Rev Caris Diagnostics Miraca 3.5x Genoptix Novartis 1.7x Clarient GE Healthcare Svcs 5.8x Genzyme Genetics LabCorp 2.5x

9 9

Business Model Targets

Pathologists and Hospital Path Groups

• Innovative technical component (TC) only services – Flow, FISH, IHC

• Enables community pathologists to compete with large labs

• Rapid turnaround-time and web-based reporting

• Extensive training programs

Oncologists and Clinician Groups • Specialized high level of service and outstanding quality for clinicians

• Genetic Pathology Solutions™ (GPS) reporting – all relevant case data on one page report

10 10

NeoGenomics’ Cancer Testing Services

Key Testing Modalities Cytogenetics: chromosome analysis - “Neighborhood view of 46 houses from 1000 feet” Flow Cytometry & IHC: cell surface marker analysis - “Single house view from 500 feet” Fluorescence in-situ Hybridization (FISH): gene analysis - “Door and window view of one house” Molecular testing: DNA/RNA analysis -“View of serial number on door lock”

11 11

• Hired Dr. Maher Albitar as Chief Medical Officer (Jan 12)

• Entered into exclusive worldwide license to Health Discovery Corp’s IP relating to pattern recognition technology, biomarker discovery, and gene & protein-based tests for cancer LDTs (Jan 12)

- Targeted initial focus areas: prostate, pancreatic and colon cancer tests; automating cytogenetics and flow cytometry analysis

• 10 Color flow cytometry (Q2 12)

• Increased IHC menu to 140 antibodies and 21 diagnostic panels (2012)

• 49 New Molecular Assays and NeoTYPE MolDx Panels (2012 - present)

• SVM-based test for ALK lung cancer FISH (Sep 12)

• NeoARRAY/SNP Cytogenetics Test (Nov 12)

• New Aperio Digital Imaging Platform (Q4 12)

• Barrett’s Esophagus FISH Test (Dec 12)

Recent Innovation

12 12

Molecular Assays Launched in 2012

Solid Tumor Assays Hematopoietic Assays

1 IDH1 & IDH2 Mutation Analysis 2 c-KIT Mutation Analysis 3 PIK3CA Mutation Analysis 4 NRAS Mutation Analysis5 TP53 Mutation Analysis6 NeoARRAY SNP/Cytogenetic

Profile7 KRAS Mutation Analysis 8 BRAF Mutation Analysis 9 EGFR Mutation Analysis

10 Microsatellite Instability Analysis11 NeoTYPE Solid Tumor Profiles:

Breast, Colorectal, Gastric, Lung & Other

12 BCR-ABL1 Translocation, t(9;22)

13ABL1 Kinase Domain Mutation Analysis

14 IgVH Mutation Analysis 15 FLT3 Mutation Analysis 16 NPM1 Mutation Analysis 17 JAK2 V617F Mutation Analysis 18 JAK2 Exon 12-14 Mutation Analysis 19 BCL2 Translocation, t(14;18)20 BCL1 Translocation, t(11;14)21 MPL Mutation Analysis 22 DNMT3A Mutation Analysis

23RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21)

24 SF3B1 Mutation Analysis 25 CBFB/NYH11, inv(16) 26 PML-RARA Translocation, t(15;17)27 WT1 mutation Analysis28 NeoTYPE CLL Prognostic Profile29 NeoTYPE AML Prognostic Panel

13 13

Accelerating Pace of Innovation

2011

4 molecular tests

3 FISH

FL – IHC menu

2012

10-color Flow Cytometry

Implemented State-of-the-art MolDx platform in lieu of Kits

29 new Molecular tests

NeoTYPE MolDx Panels

Digital Image Analysis

SVM for ALK FISH

Barrett Esophagus FISH

NeoARRAY/SNP Cytogenetics

Internalized 99% of send-outs

2013 (Planned)

20-30 new Molecular tests

Add’l NeoTYPE Panels

Next Generation Sequencing

ROS1 FISH

NeoSITE Melanoma FISH

Plasma/Urine-based Prostate Test

SVM-based Cytogenetics Analysis System

SVM-based Automated FISH Analysis System v2

14 14

NV

OR

WA

MT

MN

NE

SD

ND

ID

WY

OK

KS CO UT

TX

NM

SC

FL

GA AL MS

LA

AR

MO

IA

VA

NC

IN

KY

IL

MI WI

PA

WV

VT ME

RI

NH

AZ

OH DE MD

NY

CA

NJ

CT

MI

MA

Irvine, CA 18k sf

Nashville, TN 7k sf

Ft. Myers, FL 31k sf

A Growing Footprint

States sending specimens

Tampa, FL 5k sf

15 15

Industry Dynamics & Demographics

• Aging U.S. population and prevalence of cancer

• Diagnostic testing reduces healthcare costs and improves clinical outcomes

• Emergence of molecular diagnostics

• Targeted therapeutics and companion diagnostics

• Grow existing customer base

– Salesforce productivity

– Increase share of wallet

– Promote product education

• Attract New Customers

– Promote key advantages of “tech-only” model to community-based hospitals

– Partner with Clinician Offices

• Sustainable revenue growth opportunity • Significant degree of operating leverage in

the business model

New Products & Territories

Market Share Gains

• Continue to expand test menu

• Sublicensing of HDC products

– Cytogenetics/Flow systems

– International opportunities

• Proprietary test development

• Mergers & Acquisitions

Superior Financial Model

Key Growth Drivers

16 16

Management Team • Douglas VanOort, Chairman & CEO

Operating Partner, Summer Street Capital Partners; Chief Operating Officer, Quest Diagnostics

• Maher Albitar, M.D., Chief Medical Officer & Director of R&D Med. Dir. for Hematopathology & Oncology and Chief of R&D, Quest Nichols Institute; Director of Leukemia and Molecular Laboratory, MD Anderson Cancer Center

• Robert Gasparini, Director & Chief Scientific Officer Director of Genetics, U.S. Labs; Worldwide Marketing Mgr., Ventana Medical Systems; Asst. Director, Prenatal Diagnostic Center (Harvard)

• Steven Jones, Director, EVP – Finance, & Chief Compliance Officer Chairman, Aspen Capital Group; Managing Member, Medical Venture Partners; Vice President, Merrill Lynch Investment Banking

• George Cardoza, Chief Financial Officer CFO, Protocol Global Solutions; Controller, Central Region, Quest Diagnostics

• Robert Horel, Vice President, Sales & Marketing Regional Mgr., US Labs; Product Specialist, Ventana Medical Systems; Pilot, U.S. Navy

• Steven Ross, Chief Information Officer Vice President Technology, Chico’s FAS, Inc.

17 17

Productivity Increases Have Offset Changes in Average Revenue/Test to Keep Margins Stable

(1) Productivity calculated as the average number of lab tests completed per month per laboratory FTE. (2) The Medicare Technical Component Grandfather expiration took effect on 7/1/12, which resulted in a 7.3% sequential decrease in Avg. Unit Price.

(2)

47.3% 48.4% 46.1% 44.7% 44.6% 43.9% 44.5% 44.8% 45.2%

47.1% 47.2% 41.5%

43.2% 46.3%

-20.5%

43.4%

-50%

-40%

-30%

-20%

-10%

0%

10%

20%

30%

40%

50%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%Q

4 09

Q1

10

Q2

10

Q3

10

Q4

10

Q1

11

Q2

11

Q3

11

Q4

11

Q1

12

Q2

12

Q3

12

Q4

12

Q1

13

Gross Margin % Cum Change in Avg Rev/Test Cum Change in Productivity(1)

18 18

Quarterly Financial Information

($, 000's) Q4 11 Q1 12 Q2 12 Q3 12 * Q4 12 * Q1 13 *Total Revenue 12,893$ 15,160$ 15,611$ 14,202$ 14,893$ 15,657$ % Growth (YoY) 47.3% 72.2% 49.2% 25.5% 15.5% 3.3% % Growth (QoQ) 13.9% 17.6% 3.0% -9.0% 4.9% 5.1%

Total Gross Margin 5,834 7,144 7,367 5,892 6,434 7,246 Gross Margin % 45.2% 47.1% 47.2% 41.5% 43.2% 46.3%

Sales & Marketing Exp 1,801 2,036 1,934 1,839 1,692 1,931 General & Administrative Exp 3,530 3,750 4,066 3,930 4,097 4,175 Research & Development Exp 127 497 528 808 448 835 Total SG&A (Incl R&D) Expenses 5,459 6,283 6,528 6,576 6,237 6,942 SG&A as a % of Rev 42.3% 41.4% 41.8% 46.3% 41.9% 44.3%

Net Income/(Loss) 152$ 603$ 551$ (975)$ (113)$ 3$ Diluted EPS $0.00 $0.01 $0.01 ($0.02) ($0.00) ($0.00)

Adjusted EBITDA 1,055$ 1,775$ 1,943$ 842$ 1,439$ 1,794$

Summary Operating Data% Growth in Tests Performed (YoY) 57.2% 74.9% 57.1% 41.7% 35.3% 19.1%Avg. Revenue/Test 572$ 563$ 541$ 502$ 488$ 488$

* Quarterly financials impacted by a reduction in revenue of $1.3 MM/Qtr as a result of the expiration of the Medicare TC Grandfather Clause.

19 19

Key Financial Information

Recent Share Price (5/3/13): $ 3.67

Common Shares Outstanding: 48.7 M

Current Market Cap: $178.7 M

Diluted Shares (MRQ, Pro Forma): 50.9 M

Fully Diluted Shares: 55.8 M

Non-affiliate Float Shares: 41.1 M

52 Week Low/High: $1.55/$4.20

Avg. Daily Trading Volume (3 Mos): 228,349

20 20

NeoGenomics Summary

• Emerging leader in the fastest growing segment of the lab testing industry

• Robust competitive advantages and product portfolio

• Strong Management Team with directly relevant industry experience

• Accelerating profitability propelled by revenue growth and increased operating leverage

• Q2 2013 guidance: $15.8 - $16.4 million of revenue with $0.00 – $0.01 per share of net income

• Fiscal 2013 guidance: $68 - $73 million of revenue with $0.03 - $0.05 per share of net income